| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Verelan PM For Essential Hypertension DUBLIN, IRELAND and MEQUON, WI -- Nov. 30, 1998 – The United States Food and Drug Administration has approved Schwarz Pharma, Inc.’s Verelan(R) (verapamil HCl) PM, a chronotherapeutic form of verapamil hydrochloride, for the management of essential hypertension. Verelan PM, a calcium channel blocker, is designed for bedtime dosing and incorporates a four to five hour delay in drug delivery. The controlled onset delivery system results in a maximum plasma concentration of verapamil in the morning hours. The most frequently reported side effects of verapamil are constipation, headache and dizziness, which can be easily managed in most patients. Related Links: Verelan, Schwarz Pharma, Inc.
|